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The research and development of extracorporeal bioartiﬁcial liver is gaining pace in recent years
with the introduction of a myriad of optimally designed bioreactors with the ability to maintain
long-term viability and liver-speciﬁc functions of hepatocytes. The design considerations for
bioartiﬁcial liver are not trivial; it needs to consider factors such as the types of cell to be cultured
in the bioreactor, the bioreactor conﬁguration, the magnitude of ﬂuid-induced shear stress, nutrients’
supply, and wastes’ removal, and other relevant issues before the bioreactor is ready for testing. This
review discusses the exciting development of bioartiﬁcial liver devices, particularly the various
types of cell used in current reactor designs, the state-of-the-art culturing and cryopreservation
techniques, and the comparison among many today’s bioreactor conﬁgurations. This review will
also discuss in depth the importance of maintaining optimal mass transfer of nutrients and oxygen
partial pressure in the bioreactor system. Finally, this review will discuss the commercially available
bioreactors that are currently undergoing preclinical and clinical trials. © 2010 American Vacuum
Society. DOI: 10.1116/1.3521520
I. INTRODUCTION
Acute liver failure ALF and acute-on-chronic liver fail-
ure ACLF pose exceptionally high risk of mortality among
the liver diseases. They always require intensive life support
and subsequent organ transplantation. The pathogenesis of
these diseases comprises different pathological pathways
with the important ones being accumulation of ammonia,
upregulated systemic inﬂammation, and reversible to irre-
versible hepatocellular damage.1 Due to the scarcity of grafts
for liver transplants, extracorporeal liver support systems are
expected to play a major role in reducing complications of
the liver failure, and sustaining liver functions if the waiting
time for the actual liver transplant is prolonged. Although
there has been more than 2 decades of exploration in this
ﬁeld, further enhancements in the current systems coupled
with properly controlled clinical studies are still necessary
for the success of this application.2–4
Two types of extracorporeal liver support systems are
available; they are the artiﬁcial and the bioartiﬁcial liver.
Artiﬁcial livers are widely used in medical intensive care
units. The therapeutic purpose of artiﬁcial livers is the re-
moval of accumulated toxins in the body through their sepa-
ration and absorption in the hollow ﬁber membrane. Al-
though artiﬁcial liver is more commonly used in clinical
setting than its bioartiﬁcial counterpart, it still faces several
challenges pertaining to its clinical outcome and the valida-
tion of its therapeutic guideline.5
The idea of bioartiﬁcial liver is conceived based on the
understanding that detoxiﬁcation alone is not sufﬁcient to
replace the liver functions. It is well known that the liver is
indispensable for survival in human because there are at least
500 various functions that the healthy liver organ performs.
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Therefore, in the presence of hepatic function failure, every
liver cell-based therapy is expected to fulﬁll these urgent
physiological needs. Hence, an extracorporeal liver support
system that contains a liver cell unit, i.e., extracorporeal bio-
artiﬁcial liver EBAL, would be ideal for the substitution of
many physiologically relevant functions such as biosynthe-
sis, metabolism, and detoxiﬁcation.
The EBAL is a cell-based bioartiﬁcial liver whose core
aim is to provide most of the hepatic functions that are lack-
ing in patients with liver failure. In order that the EBAL
carry out these liver-speciﬁc functions effectively, it becomes
critical that the bioreactor be designed for optimal perfor-
mance. The role of the bioreactor is to keep these cells work-
ing physiologically for a prolonged period of time. In addi-
tion to ensure that the bioreactor is compliant with clinical
applications, the bioreactor should be reproducible, automat-
able, controllable, and customizable to cater for individual
patient’s needs. Further, to scale down this device for the
clinical setting, technical challenges such as the ex vivo cul-
turing of large masses of cells need to be addressed, so that
the bioreactor is suitable both for the cells inside and the
treated patient outside. In this review, important consider-
ations, including cell source, mass transfer, the design and
construction of the bioreactor, the EBAL conﬁguration, and
its relevant clinical evaluation, will be discussed.
II. CELL SOURCE
Liver cells are the biofunction unit in EBAL, which plays
the key role in providing organ speciﬁc function for hepatic
failure patients. Based on knowledge garnered from previous
studies involving liver resections, it is known that the main-
tenance of normal liver function can basically be satisﬁed
with about 20% of the whole liver mass, which has approxi-
mately 200 g, that is, 21010 hepatocytes. Rinkes et al.6
suggested that 10% of the entire amount of liver, about 1.5
1010 hepatocytes, is enough to perform the function of the
whole mass. At present, most of the EBALs aimed at clinical
application are loaded with 1–21010 hepatocytes,5 which
theoretically are sufﬁcient to meet the needs of clinical treat-
ment of liver function failure. However, results from the
large phase III clinical trials show that, with the treatment of
EBAL, although various biochemical parameters and clinical
symptoms can be signiﬁcantly improved in the patients, the
overall survival has not been prolonged signiﬁcantly. The
explanation for such results can be various and complicated.
To effectively evaluate the biological function of the EBAL
system, the amount of liver cells obviously cannot be the
only item to consider. It is necessary to include other critical
factors that have an important impact on the outcome of
treatment, such as the function level and viability of liver
cells before and during the treatment.7
A. Hepatocytes’ polarity
Hepatocytes, as the other epithelial cells, are highly po-
larized and are deﬁned as the symmetry of cell membrane
with the localization of different membrane proteins and lip-
ids on different membrane domains. Its unique position in
the liver served as a barrier between the blood and the bile,
and its physiological functions of substances trafﬁcking be-
tween sinusoids and bile canaliculi predominantly rely on
cell polarity. The generation of hepatocyte polarity involves
i the establishment of cell-cell and cell-matrix interactions,
ii the organization of cytoskeleton, and iii the sorting and
localization of membrane proteins. Both cell-cell and cell-
matrix interactions trigger the binding of actin ﬁlaments to
the adhesive machinery. The associations between adhesive
complex and actin ﬁlaments i reinforce the structure of
cell-cell and cell-matrix interactions and ii serve as a scaf-
fold to recruit downstream signaling molecules so that the
local cue of polarity formation can be propagated to the rest
part of the cell.
The cell membrane of hepatocytes can be divided into
three distinct domains Fig. 1: i the basal domain, which is
faced to the sinusoids for mass exchange with the blood and
can also be termed as sinusoidal domain; ii the lateral do-
main, which is the region of direct contact with the neigh-
boring hepatocytes to form cell-cell adhesion; and iii the
apical domain, which is faced to the bile canaliculi for bile
excretion and can be also termed as canalicular domain. The
basal and lateral domains are structurally continuous and are
commonly termed as basolateral domain. Tight junction
served as a structural barrier to separate basolateral and api-
cal domains. Each domain is composed of a distinct pool of
functional proteins, including adhesion proteins, receptors,
and transporters. Sinusoidal uptake and biliary excretion
highly depend on transporters to exert liver functions. In the
basolateral domain, Na+-taurocholate cotransporting
polypeptides Ntcps, organic anion transporting polypep-
tides Oatps, some family members of multidrug resistance-
associate proteins Mrps, organic anion transporters OATs,
and organic cation transporters OCTs are expressed. Ntcp is
a sodium dependent transporter for uptake of most conju-
gated bile salts and certain sulphated steroids. Oatp repre-
sents a family of sodium-independent transporters, which is
responsible for transport of conjugated and unconjugated bile
acids, neutral steroids, some organic anions such as bromo-
sulphophthalein BSP, limited organic cations, and numer-
ous drugs. OAT and OCT also belong to sodium-independent
uptake system. Their substrates remain to be found. Mrps
mediate efﬂux and are adenosine-derived nucleotide
ATP dependent. Mrp1 is for excretion of drug-glutathi-
one, -glucuronide, and -sulfate conjugates; Mrp3 is for efﬂux
of bile salts; Mrp4 and Mrp5 are for efﬂux of nucleoside
FIG. 1. Color online Segregation of membrane domains and transporter
distribution in different domains of the hepatocytes.
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analog drugs. Section II A 1 will focus on how to enhance
the biofunction of EBAL with respect to cell source, cell type
selection, cryopreservation, and transport of liver cells.
1. Cell type selection
a. Primary human hepatocytes Primary human hepato-
cytes are the ideal cells for EBAL. The beneﬁts of using
them are obvious; they include better biosafety, the satisfac-
tory level of hepatic biofunction, particularly the ability of
providing homologous biologically active substances. Poyck
et al.8 compared the metabolic functions of primary human
hepatocytes, fetal human hepatocytes, and porcine hepato-
cytes in their EBAL. They found that the ability of primary
human hepatocytes for ammonia removal and urea synthesis
was, respectively, two and three times higher than those of
porcine hepatocytes. They also discovered that the function
level of fetal human hepatocytes for lidocaine metabolism
was 3.5 times higher than that of the porcine hepatocytes,
and 6.6 times higher than the primary human hepatocytes.
However, the fetal human hepatocytes produce an extra
amount of ammonia into the culture medium, which is not
preferable for EBAL application, but more suitable for the
study of drug metabolism.
However, the primary human hepatocytes are scarce, do
not proliferate in vitro, and their normal functions cannot be
maintained optimally in vitro for longer than 1 or 2 weeks.
Most of the primary human hepatocytes used in the EBAL
for clinical trial were collected from discarded tissues pro-
ceeding from liver resection. Baccarani et al.9 collected 54
liver tissue blocks from liver resection or from whole liver
organs not suitable for transplantation and built up a primary
human hepatocyte bank. However, because most of these
samples were collected from different diseased tissues, such
as cirrhosis, ﬁbrosis, and cholangitis, the isolation was com-
paratively difﬁcult and the cell yield and viability were not
satisfying. In addition, there was a great variation of func-
tional performance among different cell batches. Besides
these, the potential contamination with viruses, bacteria, and
tumor cells was a major concern in these cells that were
destined for EBAL. Hughes et al.10 harvested livers from 20
cardiac arrest donors. The hepatocytes were isolated by the
method of collagenase perfusion with the average yield of
2.2106 hepatocytes per gram of liver mass, and the cell
viability being up to 52%, which were expected as the cell
source suitable for clinical application. But it was showed
that both the harvesting and survival rate were signiﬁcantly
affected by the length of time they were exposed to the dam-
age caused by cold ischemia and warm ischemia, meaning
that the cell functions still need to be validated in detail
before using. Therefore, making a proper choice for the tis-
sue source, improving the technology for isolation and stor-
age, and thereby building up a ready-to-use primary human
hepatocyte bank are pertinent for the EBAL.
b. Primary porcine hepatocytes Primary porcine hepato-
cytes are the preferred and the most widely used animal-
derived liver cells for EBAL due to its convenient availabil-
ity, low cost, and well-established isolation methods. They
show up more frequently in clinical reports, even entering
into clinical trials of phase II/III. Recently there has been a
considerable progress in using the cell source of primary
porcine hepatocytes, but there are still a number of draw-
backs.
1 Primary porcine hepatocytes present xenogenic antigens
to human body; thus the ﬁrst issue to be considered
when using them in clinical is the immune response gen-
erated during treatment. A study by Baquerizo et al.11
found that the levels of antipig IgG and IgM antibodies
increased signiﬁcantly in the serum of the patients who
received two or more EBAL support treatments. Schulte
arn Esch et al.12 detected the C3, C4, factor B, mem-
brane attack complex MAC, and GST in the serum
samples collected from the patients treated with primary
porcine hepatocytes charged EBAL by ELISA Sigma-
Aldrich. They found that the concentration of C3, C4,
factor B, and MAC increased gradually in the course of
the treatment. With immunohistological assay, the study
also found the human antibodies and the agglutination of
the above factors on the cell membrane of porcine hepa-
tocytes, and their concentration intensity can also be en-
hanced with the increasing number of patient treatment.
In addition, the DNA fragmentation of porcine cells in-
creased along with the number of EBAL treatment,
which showed that the immune system especially the
complement system of it in the patients treated with
EBAL was triggered to attack the porcine cells loaded
inside the EBAL. van de Kerkhove et al.13 reported that
primary porcine hepatocytes expressed Gal-alpha 1-3
Gal, which was conﬁrmed to play a critical role in the
hyperacute rejection induction in liver transplantation,
and could elicit similar reaction in the patients treated
with the EBAL containing the xenogeneic cells. To ad-
dress these problems, some other researchers14 tried to
supply the serum from liver failure patients with a kal-
likrein inhibitor, nafamostat mesilate, to prevent the im-
mune reaction against porcine cells, which signiﬁcantly
reduced the injury of porcine hepatocytes. In addition,
the production of Gal-alpha 1-3 Gal gene knockout
pigs will be a promising solution for the xenogeneic im-
mune rejection.15–17
2 Pig endogenous retrovirus PERV is a class of C-type
retroviruses common in pig tissue and cells. Although
there is no case report of PERV infection caused by the
direct exposure of human plasma to porcine cells in the
patients who received the treatment of EBAL loaded
with porcine cells, the potential dangers that it poses are
still a major concern.18 Present studies show that PERV
can infect primary human liver cells cultured in vitro,17
the endothelial cells, embryonic kidney cells 293 cells,
and the other various cell lines from rhesus monkeys,
orangutans, baboons, and other primate animals can also
be infected.19 However, when treated with high doses of
PERV and a strong immune inhibitor at the same time,
none of animals, including Romania monkey, pigtail
monkey, baboons, and other primates, was detected to be
PERV infected.20A study transplanted porcine-derived is-
let cells into immunodeﬁcient mice.21 The mice were
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divided into two groups, which were, respectively, in-
jected with normal human serum or phosphate buffer
solution PBS 2 days before the transplantation. Graft
inﬁltrating lymphocytes GILs from both groups were
harvested and analyzed at day 21 after transplantation.
The results showed that the PERV was positive in three
of the ﬁve mice in the group with PBS pretreatment, but
was not detected in the mice of the human plasma pre-
treatment group. It was speculated that PERV infection
can be blocked by the normal human plasma due to the
neutralization effect from the natural antibodies against
the heterologous antigen inside the plasma. Despite the
fact that the in vivo results can be attributed to the pro-
tective effect of the body’s immunological system, it
does not exclude the fact that there might be a high risk
of PERV infection in the patients treated with porcine
cell charged EBAL.
To minimize the risk of PERV transmission during
therapy, the semipermeable polymer membranes are nor-
mally used as barriers in the EBAL devices.22 Generation of
non-PERV pig by the technology of genetic interference can
be a promising solution as well;23 as much as 90% reduction
in PERV RNA and protein level was reported.24 However,
due to the broad existence of PERV, complete elimination of
PERV in pigs can be too difﬁcult to achieve. Therefore, other
solutions,25,26 such as administration of antiretroviral protein
reverse transcriptase/protease inhibitors e.g.,
zidovudine,27–29 and development of PERV vaccine and
anti-PERV antibodies30 are adopted to meet the needs.
c. Human liver cell lines Among the myriad strains of
human liver cell lines, C3A cell line is currently the only one
that has been permitted to be used in the clinical trial of
EBAL. C3A is derived from a clone of HepG2 cell line. It
has a higher level of albumin secretion and CYP450 activity
than HepG2. However, compared to primary porcine hepato-
cytes, C3A has a lower metabolism ability, particularly to
ammonia.31 Mavri-Damelin et al.32 used the labeled
N15H4CL to detect the ammonia removal capacity of C3A
and found that the urea generated did not contain the labeled
N15. By further analysis of reverse transcription polymerase
chain reaction RT-PCT and western blotting, the enzymes,
ornithine carbamoyl-transferase, and arginase for urea cycle
were lacking in C3A, which shows that C3A cells cannot
perform the normal ammonia metabolism, instead they pro-
duce ammonia through the pathway outside the urea cycle.
For liver failure patients who need EBAL support, the meta-
bolic transformation capacity is more compulsory and ben-
eﬁcial than biological synthesis. This is particularly critical
for the ones with hepatic encephalopathy, to whom one of
the upmost therapeutic strategies is the efﬁcient removal of
the toxicant ammonia from systemic circulation. This could
be one of the important reasons why some EBAL systems
using C3A as their biofunction performer were not able to
obtain signiﬁcant efﬁcacy in clinical treatment.
B. Coculture
In a normal liver tissue, the cell-cell, cell-extra-cellular
matrix ECM, and cell-microenvironment interactions have
been widely explored and acknowledged for their major role
in the maintenance of hepatic functions. Many studies tried
to simulate the physiological organization of liver tissue by
recruitment of the nonparenchymal cells NPCs into the
liver function unit in EBAL, and it has been shown that the
hepatic functions can be preserved for long term in the coc-
ulture system.33–37
Some soluble factors, which are believed to have impor-
tant inﬂuence on the differentiated phenotype of hepatocytes,
can continuously be generated as long as the heterogeneous
cells’ interactions are maintained in the coculture system.
Chia et al.,38 cocultured a rat primary hepatocyte with a
mouse embryonic ﬁbroblast cell line, NIH3T3 in a three-
dimensional 3D microencapsule formation and found that
the direct interactions between the cells and their secretion of
various soluble factors play an important role in enhancing
the hepatocytes’ function. Among them, transforming growth
factor TGF-1 is prominently necessary for the effects.
Ohno et al.37,39 found that in the hepatocyte-endothelial cell-
sheets layered coculture system, drug metabolism related
genes expression in the hepatocytes is upregulated, and the
ECM molecular composition and cell-adhesion molecules
changes in the system correlate with the genes expression in
a time-course pattern. The study suggested that the coculture
system can generate the beneﬁcial ECM to maintain the he-
patic function in vitro. Another study by Khetani et al.40
explored the correlation between the cocultured liver func-
tion responses and the genes expression proﬁle in different
supporting cells. Through further validation, two candidate
genes were found to play an important role in the modulation
of liver function in the coculture system, decorin related to
upregulation, while N-cadherin for the downregulation. But
neither of them alone can produce the maximal effects in the
system, which indicated that there exists the multifactorial
regulation in the cell-cell interaction. Recently, they further
examined the modulation effect of T-cadherin on liver cells’
function in vitro and found that overexpression of T-cadherin
in the cocultured cells can signiﬁcantly enhance hepatocytes’
function in a dose-dependent manner.41 All the above studies
elaborated that in the coculture system, NPCs help hepato-
cytes maintain a speciﬁc phenotype by expression of impor-
tant bioactive molecules.
C. Hepatocyte cryopreservation for EBAL
To meet the requirements of clinical practice, the supply
of cell source for EBAL must be rapid, sufﬁcient, and ready
to use. Preservation of large quantities of hepatocyte in ad-
vance is necessary to ensure that sufﬁcient cell source is
readily available for clinical purposes. Cryopreservation at
−80 or −196 °C remains the most effective method for long-
term preservation of liver cells. However, cell viability and
function of primary hepatocytes can be signiﬁcantly dam-
aged after the frozen/recovery procession. Optimization of
the cryopreservation/thawing procedures to improve the cell
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survival and the recovery of liver function is critical to ad-
dress the requirement of cell source in EBAL bioreactor con-
struction. The strategies currently taken include 1 reﬁne-
ment of the isolation technology, and incubation of the
isolated cells with medium containing antioxidants, at low
temperature, before freezing.42–44 This can effectively reduce
the isolation damage to the cells and improve their quality
prefreezing. 2 Modiﬁcation of the formula of the cryopre-
serving medium and the protective agent. Currently the Uni-
versity of Wisconsin UW solution and dimethyl sulfoxide
DMSO are still recognized as the best frozen liquid and the
most important permeable cryoprotectant, respectively.45
Making amendment to the cryopreservation medium by re-
ducing the concentration of bovine serum, adding one or a
combination of membrane stabilizers such as trehalose and
taurine,46,47 biological antioxidants such as catalase, N
acetyl cysteine, glutathione, and fetal bovine serum,48,49
apoptosis inhibitor such as Z-DEVD-FMK and
IDN-196550,51 with appropriate concentration, can signiﬁ-
cantly improve the freezing effect. 3 Optimization of the
store conﬁguration of cryopreservation. Hepatocytes are
anchorage-dependent cells; the maintenance of their func-
tions and activities depends on the support from ECM and
cell-cell communication.52 Cryopreservation conﬁgurations
such as monolayer collagen, sandwich collagen, microcar-
rier, and microcapsule stock of hepatocytes showed better
post-thawing viability and function than the suspension cell
cryopreservation. For example, HepatAssist system employs
the microcarrier adhesion of hepatocytes for cryopreserva-
tion. 4 The other factors in the process of cryopreserving/
thawing, such as type of vials,53 cell density,54 cooling rate,
and recovery procedures, also involve in the preservation
effect.45
Ultralow temperature cryopreservation, which normally
keeps the storage in liquid nitrogen, is a relatively mature
technology for long-term cryopreservation of liver cells; but
there are still shortcomings such as obvious damage of cell
viability and function, complicated operation procedure, high
cost of the programmable freezing, and inconvenience trans-
portation. Therefore, to avoid injuries caused by cryopreser-
vation such as extra- and intracellular ice formations, stresses
rising from solution effect, and dehydration, some research-
ers focus on exploring the room/low temperature preserva-
tion technology, to satisfy the requirement of simplicity, be-
ing ready to use, transportation convenience, and effective
maintenance of cell function.
Subzero nonfreezing temperature SNFT is the tempera-
ture range between 0 °C and freezing point. Ultracold tem-
perature is the range between the temperatures below freez-
ing and the temperature at which the solution begins to form
ice crystals. For UW solution, the SNFT is 0 °C− −4 °C,
and the ultracold temperature is −1 °C− −4 °C. SNFT and
ultracold temperatures not only reduce the maximum meta-
bolic activity of cells, but also avoid freezing damage caused
by ice crystal formation. Theoretically it is an ideal way for
cryopreservation of liver cells. Yoshida et al.55 preserved iso-
lated rat liver with UW solution. The treatment groups were
divided into 4 control and −0.8 °C groups. The results
showed that in the −0.8 °C group, the content of ATP and
total adenine nucleotide TAN was signiﬁcantly higher, and
the lactate dehydrogenase LDH release was lower than that
of the control group. Rodriguez et al.56 preserved rat liver
cells with UW solution, which were divided into 0, −4, and
−4 °C plus nonpermeable cryoprotectant butanediol. After
cold storage for 120 h, the survival rate and the ATP content
of cells at −4 °C were signiﬁcantly increased, higher than
those of 0 °C, while LDH release and lactic acid products
were decreased signiﬁcantly. In addition, supplementing bu-
tanediol to UW solution can further improve cell viability
and intracellular ATP content at −4 °C.
On the other hand, further progress was made in the pres-
ervation of hepatocytes at room temperature.
Epigallocatechin-3-gallate EGCG as the major component
in green tea polyphenol is found to have wide bioactivities,
such as antioxidant, anti-thrombotic, etc. Miskon et al.57 ex-
plored using EGCG as a key compound in the room tempera-
ture preservation of hepatocytes. 2109 porcine hepatocytes
were seeded in the polyaminourethan coated polytetraﬂuoro-
ethylene PTFE scaffold in a radial-ﬂow bioreactor. After
perfusion culture for 4 days, the supply of culture medium,
oxygen, and carbon dioxide was removed, and 0.25 mg/ml
EGCG was added into the medium. The preserved hepato-
cytes are kept at room temperature for another 4 days, then
washed with the incubation medium and went on culturing
for 6 days. It was found that after the room temperature
preservation, the hepatocytes still maintained good morphol-
ogy, and its functions of ammonia metabolism and albumin
synthesis, respectively, recovered to the 7216% and
9832% of the levels before treatment.
Vitriﬁcation refers to the addition of a variety of high
concentrations of cryoprotectants which act as antifreeze to
cells to produce the right degree of dehydration, and then
cool rapidly often more than 1500 °C /min. With high con-
centration of antifreeze and liquid viscosity increases, there
can be a formation of an extremely thick glasslike substance
in the amorphous state to effectively prevent the formation of
intracellular ice crystals during the rapid cooling and thaw-
ing process. The operation protocol is simple, fast, and with-
out the need of an expensive cooling device.58 Therefore,
vitriﬁcation has been widely used in stem cell,59–61 pancre-
atic islet cells, kidney, bone marrow stromal cells,62 liver
cells,63–65 and other tissue cryopreservation.
Although many studies show that vitriﬁcation is more ef-
fective than conventional slow freezing method, the toxicity
due to high concentrations of permeable cryoprotectant and
the osmotic injury produced during removal of refrigerant
are the two major shortcomings of the method. Further opti-
mization of the cryopreservation procedures for better pro-
tection of the cells and the formulation of the frozen liquid
are the core issues in this ﬁeld. Adding various substances
into the cryopreservation solution, such as sugars, hyaluronic
acid, Relaxin, salt, and antifreeze proteins, can improve the
cooling effect.
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III. MASS TRANSFER IN EBAL BIOREACTOR
A. Oxygen supply
1. Optimal oxygen tension
The most favorable oxygen tension for hepatocytes’ cul-
ture for EBAL usage can be deﬁned as a range of intracellu-
lar oxygen tension that enables hepatocytes to closely re-
semble their in vivo functionality. Ultimately oxygen is
consumed by the hepatocytes to produce ATP in the mito-
chondria or in other oxidative process such as enzymatic
addition of oxygen by Cytochrome P450. In the liver itself,
the oxygen tension varies in different regions and plays a
signiﬁcant role in compartmentalizing the metabolic and
detoxiﬁcation functions of hepatocytes, known as liver
zonation.66–68 A concise review of the role of oxygen in liver
zonation can be found in a paper by Jungermann and
Kietzmann.68
The oxygen tension of the blood in the sinusoids are
60–70 mm Hg in the periportal region, 35–60 mm Hg in the
pericentral region, and 25–35 mm Hg in the perivenous
region.69 However, due to the presence of sinusoids and the
space of Disse in between the blood and the hepatocytes, the
pericellular cell-surface oxygen tension of the hepatocytes
is approximated to be 5 mm Hg lower,70 while the intracel-
lular oxygen tension is suggested to be 15 mm Hg lower.68,71
Hence the physiological pericellular and intracellular oxygen
tensions of hepatocytes are about 20–65 and 10–55 mm Hg,
respectively.
At a hyperoxic oxygen tension, hepatocytes might un-
dergo oxidative stress and its functionality and viability com-
promised. Mitochondria and cytochrome P450 are the well-
known producers of active oxygen species such as
superoxide and hydrogen peroxide.72,73 These active oxygen
species can react with almost any cellular component and
possibly disrupt their structure or functioning.74 In a greater
than normal oxygen tension, the inherent protective mecha-
nism of the cells the antioxidant enzymes could be over-
whelmed resulting in cytotoxicity.75
Many researchers ﬁnd the reported optimal range in vitro
oxygen tension of hepatocytes culture from these following
studies as controversial.76,77 Yanagi et al.76 found that a high
oxygen concentration of 460 M 387 mm Hg of oxygen
improves the metabolic activities of the hepatocytes in a
packed bed reactor signiﬁcantly, and Custer and Mullon78
reported that no oxygen toxicity is observed in the range
152–532 mm Hg. On the other hand, Nishikawa et al.79
found that hepatocytes cultured under 20% atmospheric oxy-
gen tension 152 mm Hg perform most effectively, while
Miyazaki et al.80 found that hepatocytes cultured under nor-
mal air 160 mm Hg experienced hyperoxic condition that
compromises their viability. Likewise Badera et al.81 showed
that rat hepatocytes undergo oxidative stress when cultured
at atmospheric oxygen tension of 160 mm Hg, and Suleiman
and Stevens75 found that above 132 M or 111 mm Hg us-
ing oxygen solubility value of 1.19 nmol cm3 mm Hg−182
oxygen concentration, the viability of the hepatocytes gradu-
ally decreases in the early stage of culture probably due to
oxidative damage.
To overcome this ambiguity and seemingly incongruous
data, a possible solution is to report instead the pericellular
oxygen tension. A study by Wolff et al.83 indeed found that
incubation gas oxygen tension is insufﬁcient to predict the
Epo production rate of human hepatoma cell lines, instead it
found a clear correlation between Epo production and peri-
cellular oxygen tension. Suleiman and Stevens’ value should
be somewhat closer to the pericellular oxygen tension as they
use a well-stirred culture medium, though an experiment in
1970 has shown that oxygen depletion region around the
cells still occurs despite vigorous mixing.84 It could also be
the case for the value of Badera et al., as they used a
collagen-coated oxygen-permeable bottom directly below the
cultured cells, depending on the thickness of the collagen
layer. Hence, the upper threshold for pericellular oxygen ten-
sion where no oxygen toxicity occurs is probably in the 90–
111 mm Hg range.
Studies by Subramanian et al.71 and Schumacker et al.85
present many important insights about hepatocyte metabolic
activity, in relation to the oxygen tension of the culture me-
dia. Note that the following reported oxygen tension values
were measured from well-stirred culture media. Essentially
they found that the cellular ATP decreases when the oxy-
gen tension is slowly decreased below 100 mm Hg. As the
availability of the oxygen decreases, mitochondria uptake
rate of oxygen decreases and ATP production decreases. To
avoid eventual total depletion of the cellular ATP, as would
be the case when consumption rate is larger than the produc-
tion rate, the intrinsic ATP demand of the cell is downregu-
lated. To maintain viability, only the “nonessential” ATPases
are reversibly suppressed while ATPases that are crucial for
cell viability e.g., Na–K ATPases are maintained.71 This
selective suppression can be possibly explained by the vary-
ing ATP afﬁnities of different enzyme systems.85 It can also
be seen from their results that the intracellular ATP, and not
the oxygen tension, correlates closely with the oxygen up-
take rate of the cell. It is unknown whether the level of
metabolic activities and the oxygen uptake rate of the hepa-
tocyte is inﬂuenced directly by the intracellular ATP and/or
through an unknown oxygen sensor that is able to modulate
speciﬁc genes expression.
It is possible that the above-mentioned modulation of in-
tracellular ATP through oxygen availability is involved in
the creation of liver zonation in vivo. The suppression of
acetaminophen detoxiﬁcation at 20 mm Hg oxygen tension71
is consistent with the ﬁnding of a study using intact liver that
the in vivo rates of glucuronidation and sulfation are greater
in the periportal region.86 Other periportal-zonated functions,
gluconeogenesis, urea, and albumin synthesis,68 are compro-
mised at lower oxygen concentration.87,88 On the other hand,
certain metabolic functions such as erythroprotein EPO
production,89 glycolysis,68 CYP1A1,90 and CYP2B
expression66 are improved under lower perivenous oxygen
tension.
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In conclusion, it is desirable that the pericellular oxygen
tension of the hepatocytes in a perfused bioreactor mimics
the in vivo physiological counterpart so as to be able to per-
form liver functions found in various zones. Exceeding it
could cause oxidative stress, while having less than it will
cause undesirable extensive suppression of functions and
even cell death.
2. Oxygen uptake rate of hepatocyte
To be able to supply an appropriate amount of oxygen for
hepatocytes’ culture, the knowledge of hepatocytes’ oxygen
uptake rate OUR is important. The OUR of hepatocytes is
often modeled according to Michaelis–Menten MM kinet-
ics as it has been shown to reasonably match the experimen-
tal data.91 This model represents the manner in which the
OUR of the hepatocyte decreases in response to a decrease in
local oxygen tension, as have been discussed earlier. The
values of Vm, the maximum OUR, and Km, the oxygen ten-
sion that corresponds to half Vm OUR, can be found through
experiments.
The OURs of hepatocytes have been found to vary be-
tween species, time phase of culture, cell density, and usage
of NPCs. Balis et al.92 measured the Vm of porcine hepato-
cytes to be 0.9 nmol s−1 million cells−1 at day 4, which de-
creased gradually to 0.31 nmol s−1 million cells−1 by day
15, while the Km value is 2 mm Hg at day 2, increased to 8
mm Hg at day 8, and decreased to 4 mm Hg by day 15. On
the other hand, Rotem et al.93 experiment revealed that the
Vm of rat hepatocyte was about
0.34 nmol s−1 million cells−1 during the ﬁrst day and stabi-
lized to 0.27 nmol s−1 million cells−1 afterwards.
The higher Vm at the early phase of culture is attributed to
the high energy requirement for the hepatocytes to
spread.93,92 The application of this knowledge has been
shown by a study in which immobilization efﬁciency of
hepatocytes improves at higher oxygen concentration 30%
or 40% oxygen in the atmosphere.94 This seems to contra-
dict Suleiman and Stevens’ ﬁnding that cell viability de-
creases signiﬁcantly at and above 20% atmosphere oxygen
during the early culture period due to oxidative damage.75 A
possible explanation is that Suleiman and Stevens pre-
equilibrate their culture medium with the atmosphere, creat-
ing immediate hyperoxic pericellular oxygen tension, while
Yanagi and Ohshima did not, and hyperoxic pericellular oxy-
gen tension was never developed due to oxygen gradient
formation in the culture medium.
The effect of cell density toward the OUR of hepatocytes
is still not clear. Guarino et al.95 found that hepatocytes are
metabolically more active and hence consume more oxygen
when the cell to cell contact is enhanced by increasing cell
culture density. On the other hand, Patzer77 theorized that a
high cell density closely resembles the natural in vivo condi-
tion and creates less stressful condition for the hepatocytes,
hence explaining the observed decrease of the OUR in some
experiments when the cell seeding density is high. Cho et
al.96 showed that the Vm of hepatocytes cocultured with
3T3-J2 ﬁbroblasts varied according to the hepatocyte to ﬁ-
broblast ratio, with lower ratio causing an increase in hepa-
tocyte Vm. Interestingly, the resultant increase in the OUR
was observed to correlate well with the increase in urea syn-
thesis and albumin secretion. It remains to be seen whether
this increase in Vm correlates with intracellular ATP, as has
been discussed previously.
B. Effect of shear stress on hepatocyte culture
In vivo, blood ﬂow will directly induce shear stress on
hepatic sinusoids, and through the fenestra, on hepatocytes
and the NPCs. These cells are known to response to shear
stress probably in independent and interdependent manners.
A well-known example is the induction of PAI-1 gene ex-
pression in hepatocytes97 and nitric oxide NO secretion by
endothelia cells98 in response to increased shear stress fol-
lowing a partial hepatectomy, in which both are involved in
liver regeneration process.
The value of shear stress on the sinusoids can be as high
as 20–40 dyn /cm2.99 While the values for the rest are
unknown,97 we can expect them to be signiﬁcantly lower,
considering the shielding effect of sinusoids and the presence
of space of Disse. In a study using liver slices, moderate
shear stress after 12 h was found to maintain cytoplasmic
membrane integrity and improved albumin production unlike
no shear stress or high shear stress condition.100 The exact
value of moderate shear stress is unclear but it was stated as
between 0.5 and 20 dyn /cm2.
The creation of an EBAL necessitates the use of perfusion
culture to improve mass exchange e.g., oxygen supply or
waste removal, which unavoidably imposes shear stress on
the cells. Though many studies have been done to ﬁnd out
the acceptable or beneﬁcial shear stress values for hepato-
cytes’ culture, no consensus has been achieved yet. Indeed’
as we discuss further into this topic’ we might ﬁnd that the
effect of shear stress for different in vitro culture setups e.g.,
cell species, presence of NPCs, or ﬂuid-cell membrane bar-
rier, culture period, and functions e.g., cytochrome P450
superfamily CYP activity or urea synthesis might be in-
herently different.
In a study by Kan et al.99 using rat hepatocytes’ coculture
system, shear stress 4.7 dyn /cm2 was found to induce
NPCs’ secretion of extracellular matrix, which in turn en-
ables hepatocyte-NPC reorganization into aggregates that
perform signiﬁcantly better functionally. This enhancement
is attributed to a better cell-cell interaction and the NPC-
secreted extracellular matrix. Interestingly, by having 7 day
preperfusion stationary culture period, the hepatocytes per-
form better as compared to having lesser period or none.
This ﬁnding has to be applied carefully for other culture
conditions, where NPCs are absent, or sinusoids, which in
itself also inﬂuence hepatocytes functioning in response to
shear stress,99 are present, or overlaying membrane, which
might restrict aggregate formation, is used.
Short-term 3 days study of rat hepatocytes’ coculture
ﬁnds that lower wall shear stress group
0.01–0.33 dyn /cm2 performs better than higher shear
stress group 5–21 dyn /cm2 in terms of urea and albumin
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production.101 Looking at the albumin production for 10 day
perfused culture under 0.33 dyn /cm2, a sudden signiﬁcant
improvement was not observed on any day. This is unlike the
result of Kan et al., which shows a signiﬁcant improvement
of albumin production on day 4. This could mean that
0.33 dyn /cm2 is too low to induce NPCs’ secretion of extra-
cellular matrix, which allows beneﬁcial aggregate formation.
Further study is needed to compare the long-term 7 days or
more hepatocytes’ coculture functioning under low and high
shear stresses. As for detoxiﬁcation function, a study of rat
hepatocytes’ coculture found that a shear stress as high as
10 dyn /cm2 does not adversely affect CYP1A1 activity for
at least 12 h.
A recent study using human hepatocytes homotypic cul-
tured in perfused microchip bioreactors under various shear
stresses of 1.4–60 dyn /cm2 has found that albumin produc-
tion is optimized at the lowest shear stress for at least 3
days.102 The study has also found that the cell shape of hepa-
tocytes remained in the same shape as in static culture when
cultured below 5 dyn /cm2.
Overlaying membrane is utilized in a sandwich system as
a polarity cue to improve hepatocyte functioning. It is pos-
sible that the membrane acts as a mechanically shield and
reduces the shear stress acting on the hepatocytes.103 This
could work in two ways by partially “absorbing” the force
generated by the shear ﬂow or by smoothening the ﬂuid-solid
interface. To elaborate the latter point, ﬁrst we have to un-
derstand that on the cell surface itself, there exists maximal
shear stress region usually around the cell apex due to un-
even cell contours.104 The presence of membrane can argu-
ably help to even out the contour and change the shear stress
distribution pattern.
Interestingly, our experiences with sandwich culture indi-
cate that sandwich culture could be more sensitive to shear
stress. This can probably be explained if hepatocyte employs
focal adhesion FA as part of mechanosensory device. Since
shear stressed membrane is directly attached to ECM, higher
tension might be generated to the focal adhesion than nor-
mally absence of overlaying membrane would with the
same ﬂuid ﬂow rate. FA has been implicated as the mecha-
nosensors in many cells.105,106
C. Computer ﬂuid dynamic „CFD… modeling of EBAL
CFD is a computational technology that enables the cre-
ation of ﬂuid model on which the desired physical and
chemical phenomena can be imposed through the application
of appropriate mathematical equations. CFD involves simul-
taneously solving ﬂuid motion equation the Navier–Stokes
equations are commonly used with other applicable equa-
tions e.g., mass transfer equation using the appropriate
boundary conditions. A fundamental aspect of CFD is the use
of computer to solve the representative mathematical equa-
tions with numerical methods that involve discretization pro-
cess using ﬁnite difference, ﬁnite element, and ﬁnite volume
methods. CFD inherently possesses a weakness that only
approximate solution can be achieved, though with proper
discretization reasonably accurate solutions can be obtained.
Theoretically CFD enables the simulation of ﬂuid with any
geometry under any physical and chemical phenomena.
Typically, CFD simulation for EBAL is used to ﬁnd ﬂow
velocity, shear stress, and oxygen tension proﬁle, which
sometimes are impossible to obtain experimentally. More-
over, CFD simulation enables optimization of EBAL design
without the need of physical testing, which translates into a
faster and cost-effective product development. Validation of
model commonly involves comparing the outlet oxygen ten-
sion or the oxygen consumption rate between the simulated
and experimental results.
With commercially available CFD software, such as AN-
SYS CFD ANSYS Inc., Canonsburg, PA, COMSOL MULT-
IPHYSICS COMSOL Inc., Burlington, MA, or ADINA
ADINA R&D Inc., Watertown, MA, bioreactor models
with complex features and geometry have been simulated, as
will be listed out in the subsequent paragraphs. Though usu-
ally signiﬁcantly more costly than MATLAB, it has the advan-
tages of having a user-friendly interface, an in-built graphical
interface, and in-built mathematical equations and solvers.
3D CFD simulation of a ﬂat-plate bioreactor using FLU-
ENT ANSYS Inc., Canonsburg, PA reveals the possible
limitation of two-dimensional 2D modeling.107 In the real
case 3D, the ﬂuid velocity varies in the width z direction
as well, and hence the ratio of channel height to width has to
be signiﬁcantly low for the 2D assumption to be reasonable.
Speciﬁcally, for oxygen transport problem, the 2D model so-
lution will be signiﬁcantly different if the Damkohler number
is below 0.5 and the Peclet number is below 1000.
2D CFD simulation of hollow ﬁber bioreactor using FEM-
LAB now known as COMSOL MULTIPHYSICS was done with
axisymmetry but without the radial-only diffusion
assumption.108 Besides implementing MM oxygen consump-
tion of hepatocytes, hemoglobin model as an oxygen carrier
is also included.
Rotating hollow ﬁber bioreactor for artiﬁcial liver has
been simulated using FLUENT, in which 2D model was cre-
ated to ﬁnd the optimum rotating speed for best multiphase
microcarrier-attached aggregated cells and culture medium
mixing, and 3D model was created to simulate the oxygen
tension proﬁle and ﬂuid-induced stress of the ﬂoating
aggregates.109
Radial-ﬂow bioreactor consisting of a stack of circular
microgrooved glass substrates was simulated with ANSYS
CFD FLOTRAN.110 This bioreactor has a relatively complex
ﬂow pattern in which medium ﬂows from the peripheral edge
toward the central vertical channel where the axisymmetry
line is located at. The role of microgrooves to reduce shear
stress imposed on hepatocytes/ﬁbroblast cocultures has been
shown through the use of simulation. In addition, the oxygen
tension proﬁle has also been simulated and validated by
comparing the simulated and experimentally measured outlet
oxygen tension. In this simulation, the OUR of the cells is
assumed to be a constant equal to the Vm value, which is
reasonable if the oxygen tension is signiﬁcantly larger than
the Km value.
A macrofabricated array bioreactor for 3D liver culture
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was simulated using ADINA.110 The hepatocytes are seeded
inside microchannels in which culture medium is perfused
through them. 3D models of the whole bioreactor and also a
representative tissue-ﬁlled microchannel were created to ﬁnd
the relevant shear stress values. The hepatocyte tissue inside
the microchannel is modeled as a rigid solid with the no slip
boundary condition.
IV. EBAL BIOREACTOR CONFIGURATION
The use of EBAL in treatment of liver failure is based on
the assumption that detoxiﬁcation, intermediate metabolism,
and macromolecule synthesis function can be provided by
hepatocytes cultured in the bioreactor of the EBAL.5 How-
ever, the long-term maintenance of hepatocyte differentiated
functions in vitro remains a challenging ﬁeld. Since hepato-
cytes are anchorage-dependent cells, various biomaterials for
in vitro hepatocyte culture such as membrane, microcarriers,
polymeric matrix, or scaffold are incorporated in bioreactor
design for cell attachment. There are mainly four different
bioreactor conﬁgurations under current investigation: hollow
ﬁber cartridges, encapsulation system, packed bed, and ﬂat
plate. The features of eight EBALs under clinical trials are
summarized in Table I.
A. Hollow ﬁber cartridge
Hollow ﬁber system is the most common bioreactor con-
ﬁguration. Generally, a hollow ﬁber bioreactor consists of a
cylindrical column with hundreds of thousands of hollow
ﬁbers aligned longitudinally through the column. Cells are
cultured outside the hollow ﬁber while culture medium or
patient’s blood/plasma is perfused in the ﬁber lumen along
the hollow ﬁber. The hollow ﬁbers are made from semiper-
meable membranes, which allow mass transfer across the
membrane between cells and perfusate. However, many re-
search groups modiﬁed the basic design of hollow ﬁber
bioreactor to improve the performance.
The majority of EBALs under various stages of clinical
trials are based on hollow ﬁber conﬁguration. They use dif-
ferent culture techniques for cell anchorage outside the hol-
low ﬁbers. In an extracorporeal liver assist device ELAD
developed by Ellis et al.,111 human hepatocyte cell line, C3A,
is directly seeded and grown to conﬂuence in the extralumi-
nal space of hollow ﬁbers. The Excorp Medical bioartiﬁcial
liver support system BLSS uses primary porcine hepato-
cytes as cell source. Cells are mixed with collagen to infuse
into hollow ﬁber bioreactor so that collagen gel matrix is
formed in the extracapillary region for cell anchorage.112
Detry et al.113 developed HepatAssist 2000, in which
collagen-coated dextran microcarriers are used for porcine
hepatocytes attached and are housed in the extracapillary
compartment in the bioreactor. The Academic Medical Cen-
ter AMC EBAL system loads a nonwoven hydrophilic
polyester matrix in the extraﬁber region in the bioreactor for
hepatocytes’ attachment while the inner-lumen of hollow ﬁ-
bers are used for oxygen supply.114 Sauer et al.115 developed
a modular extracorporeal liver support MELS with a more
complex interwoven hollow ﬁber cartridge. Three different
bundles of hollow ﬁbers are interwoven to form a three-
dimensional framework so that each bundle can perform
separate functions such as plasma inﬂow, plasma outﬂow,
and oxygen supply. Hepatocytes are cultured with a collagen
matrix outside, or between, the hollow ﬁbers. In this design,
each hollow ﬁber supplies nutrients for only several hepato-
cytes so as to reduce nutrients’ gradient in the perfusion. The
system also allows hepatocytes’ coculture with other NPCs
to form a tissuelike structure, and the formation of bile
canaliculi was observed. In China, the preclinical or clinical
trials of hollow ﬁber EBALs are conducted by several
groups, such as the TECA type hybrid artiﬁcial liver support
system TECA-HALSS developed by Chinese People Lib-
eration Army PLA general hospital in Beijing,116 the hybrid
bioartiﬁcial liver HEBAL by the Nanjing University,117 the
novel bioartiﬁcial liver NEBAL by the Zhejiang
University,118 and the bioartiﬁcial liver support system
BALSS by the Southern Medical University.119 The com-
mon feature shared by these EBALs is the combination of a
hollow ﬁber-based system with other nonbiological modules
such as charcoal absorbent or plasma exchange modules to
improve treatment outcome.
Three hollow ﬁber EBALs with distinct feature are in
preclinical or in vitro test. The LIVER-X 2000 system devel-
oped in the University of Minnesota has hepatocytes seeded
in the lumen of a hollow ﬁber instead of the extraluminal
space while patient’s blood was perfused between ﬁbers.120
Jasmund et al. in Eberhard Karls University developed the
oxygenating hollow ﬁber bioreactor OXY-HFB in which
hepatocyte seeding and blood perfusion are both in the ex-
traﬁber space, allowing direct contact of hepatocytes and
blood.121 The hollow ﬁbers are used for oxygen supply and
temperature control. Mizumoto and Funatsu122 applied a cen-
trifugal force for hepatocytes’ inoculation in their liver lob-
ulelike structure LLS module EBAL so that hepatocytes
can form an organoid structure in the outer space of hollow
ﬁbers.
B. Packed bed system
Packed bed, originally used as a term in chemical engi-
neering, refers to a hollow vessel that is ﬁlled with packing
materials. In application of EBAL, this conﬁguration can be
used to ﬁll matrix for hepatocyte attachment and perfused
with medium or patient’s blood/plasma. Various packing ma-
terials for hepatocyte entrapment, such as microchanneled
polyurethane foam,123 polyvinyl resin cubes,76 alginate
beads,124 porous hydroxyapatite beads,125 and polyester fab-
ric cell scaffold126 were explored. The radial-ﬂow bioreactor
RFB EBAL system, designed in the University of Ferrara,
is the only packed bed conﬁguration under clinical trial.127 In
the bioreactor, hepatocytes are entrapped within the woven
polyester microﬁbers and patient’s plasma is perfused from
the center to the peripheral of packed bed allowing the direct
contact of hepatocytes to plasma, whereas in some other sys-
tems, the perfusion pathway is reversed.
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C. Encapsulation system
In an encapsulation system, hepatocytes are enveloped in
a polymeric matrix to form a small capsule and encapsulated
hepatocytes are packed in a chamber for perfusion. Various
materials have been used for hepatocyte encapsulation, in-
cluding hydrogels,128 alginate,129 and copolymer such as hy-
droxyethyl methacrylate-methyl methacrylate
HEMA-MMA.130 In some systems, hepatocytes form sphe-
roids before entrapped into a capsule,131,132 because there are
evidences showing that spheroid enhances cell-cell
interaction,133 and facilitates the formation of bile-duct struc-
ture between cells to improve cell functions. However, there
are no EBAL of encapsulation conﬁguration under clinical
trial so far.
D. Flat-plate system
Hepatocytes’ monolayer culture on the substratum such as
collagen, laminin, ﬁbronectin, or Matrigel is a common in
vitro culture method. Overlay of a matrix gel layer on the top
of monolayer culture to form a sandwich conﬁguration sta-
bilizes hepatocytes’ cuboidal structure. The establishment of
hepatocyte polarity and maintenance of differentiated func-
tions for several weeks can be achieved.103,134 The pioneer to
employ ﬂat plate conﬁguration in EBAL application is
Uchino et al.135 in 1987 who stacked 200 hepatocyte mono-
layers on a collagen-coated glass plate and conﬁrmed the
efﬁcacy of EBAL treatment in anhepatic dogs to extend their
survival time. They further improved the results by replacing
monolayer culture with sandwich culture, and better hepato-
cyte functions in stacked collagen sandwich bioreactor mod-
ule were evident.136 A full-scale ﬂat membrane bioreactor
FMB based on sandwich culture was developed in
Germany.137 Each stackable FMB module is 1150 cm2 and
up to 50 modules can be perfused in parallel. Park et al.138
developed a radial-ﬂow bioreactor with stacked microfabri-
cated grooved substratum in which the grooved glass plate
protected hepatocytes from negative impact of ﬂow shear
stress. Sandwich culture is considered to be one of the best in
vitro hepatocyte culture models. However, the application of
sandwich culture in EBAL bioreactor design is stagnant
since several technical difﬁculties, such as relatively low cell
housing capacity compared to other conﬁgurations and labor-
intensive bioreactor assembly, need to be addressed in future
bioreactor design.
E. Microﬂuidic chip based system
Microfabrication based microﬂuidic system for hepato-
cyte culture has emerged as a promising area for various
hepatocyte in vitro applications including EBAL. The ﬁne
control of hepatocyte microenvironment, which is essential
to maintain hepatocyte differentiated functions, is made pos-
sible at microscales in microﬂuidic system. The small ﬂuid
volume in microﬂuidic perfusion allows more efﬁcient mass
transfer in terms of delivery and removal of soluble
substance.139 Lee et al.140 created an artiﬁcial liver sinusoid
with a microﬂuidic endothelial-like barrier and rat or human
hepatocyte can be cultured within the barrier. Hepatocyte
viability and drug metabolism functions can be maintained
for 7 days in the system. The ﬁrst attempt to design a micro-
ﬂuidic system based bioreactor for EBAL was by Leclerc et
al.141 from the University of Tokyo. Ten microfabricated
polydimethylsiloxane PDMS chips were stacked to consti-
tute four interconnected cell culture chambers and one oxy-
gen supply compartment. The microﬂuidic bioreactor
can achieve high cell seeding density of
30–40 million cells /cm3 with efﬁcient mass transfer, which
demonstrated its potential of scalability for EBAL applica-
tion.
V. CLINICAL EVALUATION
Comprehensive clinical research is carried out in some
EBALs. The experiences gained from these clinical trials
have provided scientists useful insights into the bioengineer-
ing and clinical aspects of the bioreactor designs. These cru-
cial lessons will allow us a step closer to the realization of a
clinically validated EBAL that can provide long-term support
for patients with liver failure. Section IV will report the latest
clinical trials of several EBALs.
A. HepatAssist
HepatAssist, now renamed HepaMate, is one of the
EBALs that have been most clinically investigated.142
HepatAssist was extensively evaluated by phase I clinical
trial. The clinical research achievement of HepatAssits was
seen as a milestone in the area of EBAL R&D. The bioreac-
tor of HepatAssit is based on the hollow ﬁber conﬁguration
with 5–7109 cryopreserved primary porcine hepatocytes
attached on microcarrier culturing in its extracapillary space.
Plasma separated from patient’s blood passes a charcoal ab-
sorber and an oxygenator before ﬁltering through a 0.2um
thickness membrane to reach the cells for biological mass
exchange. The detoxiﬁed plasma will be combined with
blood cells and return to the patient.
In an uncontrolled clinical study of 39 ALF patients
treated with HepatAssist,143 32 patients successfully bridged
to liver transplant, 6 patients had spontaneous recovery
through HepatAssist therapy, of whom 5 were ALF caused
by acetaminophen overdose and the 1 month survival rate
was 90%. In another controlled clinical study,144 13 patients
with stage III or IV hepatic encephalopathy, which needs
emergency liver transplant, received HepatAssist treatment.
10 of them successfully completed liver transplant in the
9–110 h, 2 had spontaneous recovery, and 1 moved to emer-
gency liver transplant before HepatAssist treatment. The
neuropsychological symptom of the patients receiving treat-
ment was signiﬁcantly improved, with the Glasgow Coma
Scale score from 6.53.7 down to 9.64.4, the bilirubin
and transaminase levels decreased signiﬁcantly. 1 year sur-
vival rate was 80%. Although therapeutic complications such
as transient hemodynamic instability and bleeding occurred
in some patients, retroviral infection, immune rejection, and
the other serious complications did not happen. The beneﬁ-
cial effects shown in the above studies encouraged HepatAs-
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sist to further evaluate its clinical potential. For this purpose,
Demetriou et al.145 reported a large randomized, controlled
multicenter trial with a total of 171 patients with fulminant/
subfulminant liver failure and primary nonfunction following
liver transplantation. In the study, 86 cases received standard
medical treatment SMT, and 85 patients received the treat-
ment of HepatAssist. The results showed that although the
plasma bilirubin level of the HepatAssist group was signiﬁ-
cantly lower than the SMT group, and survival in fulminant/
subfulminant liver failure patients of the HepatAssist group
was signiﬁcantly higher than the SMT group 70% versus
37%, for the entire patient group, there was no signiﬁcant
difference in the 30-day survival of HepatAssist versus SMT
71% versus 62%. The main reasons for such results may
include the following factors: 1 the impact of liver trans-
plant. There were 55% of the 171 patients who received liver
transplant in the study, although it took, respectively, 5 and 3
days for the EBAL and SMT groups before moving to the
operation, the survival of the ALF patients was dominantly
determined by liver transplantation; 2 the difference in the
etiology and severity of ALF patients included in the study.
The diversity in the disease itself will have an important
impact on the clinical outcome; 3 the utmost complexity of
ALF interventions, in addition of the signiﬁcant variation in
the standard of therapy among the treatment centers, makes
it hard to uniformly evaluate the efﬁcacy of the individual
treatments; 4 the number of patients included in such com-
plicated clinical research was not statistically enough; 5 the
exact mechanism of HepatAssist’s effect to ALF patients was
still unclear. The outcome of the study provides the succes-
sors with precious reference.
B. Extracorporeal liver assist device
Extracorporeal liver assist device ELAD, developed by
Sussman et al.,146 is another hollow ﬁber bioreactor based
EBAL. The same as HepatAssist systems, it has completed
the controlled clinical trials. The cell source charged in
ELAD is the human cell line, C3A. About 200 g of C3A cells
are used in its modiﬁed dialysis cartridge. The cells are sepa-
rated from patient plasma by the 75KD capillary membrane.
The ﬁrst human application of ELAD was for a female
patient with liver failure.147 After a period of 6 days of treat-
ment, both neurological symptoms and clinical parameters
were signiﬁcantly improved, and the treatment was sus-
pended. Unfortunately, the patient died of sepsis a few days
later. In its pilot clinical study, ELAD had its short-term
safety and metabolic support efﬁcacy tested through the
treatment of ten patients with ALF and one with primary
nonfunction PNF.146 In the study, clinical symptoms of ten
patients were improved; six patients successfully completed
or avoided liver transplant; and medical complications such
as hemodynamic instability, complement system activation,
or vital organ function failure did not happen.
In the following pilot controlled clinical study of ELAD,
Ellis et al.111 reported that a total of 24 ALF patients divided
into two groups, the one with the expectation of potential
recovery and another one with critical requirement for liver
transplant, randomly received EBAL treatment together with
SMT, or the sole SMT control. In the group with recovery
potential, the survival for EBAL treatment versus the control
was 78% versus 75%, while in another group, it was 33%
versus 25%. There were no statistical differences between
the two treatments, and the ammonia and bilirubin levels in
patients receiving ELAD hemoperfusion were 8% and 20%
higher than those before treatment. Therefore, its efﬁcacy
still needs further validation.
To further enhance the safety and efﬁcacy of ELAD, Mil-
lis et al.148 modiﬁed its bioreactor in the following aspects:
1 to promote the mass exchange between the plasma and
the cells, the semipermeable membrane pore size was in-
creased from 70KD to 120KD, and the perfusion rate of
150–200 ml/min was changed into 500 ml/min; 2 to in-
crease the cell mass from 200 to 400 g; 3 to set the online
dynamic monitoring of oxygen and glucose consumption in
the bioreactor in order to understand the metabolic activity of
the liver cells; 4 to add an extra ﬁlter in the circulatory
system to prevent the cell leakage into patient; and 5 to
amend the oxygenation device in the system for further im-
provement of the oxygen level in the bioreactor. With these
improvements, C3A cells in the ELAD system can maintain
effective metabolic activity even after 12–107 h of treatment.
With the modiﬁed system support, ﬁve ALF patients success-
fully completed their liver transplant operation, and the 30-
day survival was 80%. Neither the improvement of patients’
biochemical parameters nor obvious adverse reaction had
been observed. Now ELAD is in its clinical trials for acute-
on-chronic patients in China and United States, its therapeu-
tic effectiveness remains to be further tested.2
C. AMC-bioartiﬁcial liver
AMC-bioartiﬁcial liver AMC-BAL, developed by Flen-
drig et al.149 in the Academic Medical Center of the Univer-
sity of Amsterdam, has its bioreactor uniquely designed of
two sheets of spirally wound nonwoven hydrophilic polyes-
ter scaffold with 11010 porcine primary hepatocyte aggre-
gates growing on it, and an integrated hydrophobic hollow
ﬁber between the two sheets to homogeneously supply oxy-
gen and remove CO2. When plasma is perfused through the
extraﬁber space, it will directly contact the hepatocytes,
which can prevent membrane from fouling block during the
process of mass exchange, and be beneﬁcial for oxygenation
in the bioreactor. Therefore the efﬁciency of mass exchange
was signiﬁcantly improved in the AMC-BAL bioreactor than
the other hollow ﬁber bioreactors.
AMC-BAL began its phase I clinical trial in Italy.114 In
the study, seven cases of coma grade III or IV ALF patients
received 8–35 h of treatment with AMC-BAL. All patients
had improved neurological function, and the blood concen-
trations of bilirubin and ammonia decreased by 31% and
44%. Six cases were successfully bridged to liver transplant,
one underwent liver function recovery after two treatments,
without the need of liver transplant. Except for two cases of
transient hypotension, no other adverse reactions occurred.
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However, since then, many European countries set up le-
gal constraints for xenotransplantation. AMC-BAL group
had to suspend the clinical trial research due to the use of
porcine hepatocytes, and dedicated themselves to the optimi-
zation of bioreactor oxygenation and rheological design as
well as the development of human liver cell source.150
Although clinical studies showed that AMC-BAL had ef-
fects on the survival of ALF patients, but there remained
issues to be addressed such as inadequate perfusion of oxy-
gen and ﬂuid inside the bioreactor, which leads to the func-
tion of the liver cells dropped dramatically to 25% after 3
days of culture.151 With further optimization, dead space in
the bioreactor was reduced so that the biofunction of liver
cells was kept at 80%–90% of day 1 after 3 day
cultivation.152 In addition, Mareels et al.153 reported their
application of rheological numerical model for the optimiza-
tion the distribution of oxygen in the AMC bioreactor. How-
ever, it has yet reported the clinical studies with optimized
bioreactor AMC. Therefore its safety and efﬁcacy for the
ultimate clinical application remain waiting for the large,
randomized, controlled clinical trials.
D. Excorp medical bioartiﬁcial liver support system
The Excorp medical bioartiﬁcial liver support system
BLSS, developed by the University of Pittsburgh
McGowan Institute, has the hollow ﬁber bioreactor car-
tridge loaded with 70–100 g of porcine primary hepatocytes
mixed with collagen gel.154 The whole blood gets oxygen-
ated before entering into the bioreactor, where it exchanges
mass with liver cells through a semipermeable membrane
100KD. The ﬁrst case of treatment with BLSS is a 4l-year-
old female patient with ALF.155 After treatment, the patient
had the concentrations of ammonia, lactate, and total biliru-
bin decreased, coagulation function and clinical symptoms
improved, and eventually removed off the BLSS treatment.
There was another study that reported four cases with ALF
treated with BLSS.112 All the four patients could tolerate the
treatment well, and the average levels of ammonia and total
bilirubin levels were lower than before treatment by 33% and
6%. During the hemoperfusion, except for the hypoglycemia
of four patients at the start phase, and the low blood pressure
of one patient that was corrected promptly, there were no
other serious complications. And there was no PERV infec-
tion detected in all the patients in 1 year after the treatment.
E. Modular extracorporeal liver support
Modular extracorporeal liver support MELS, developed
by the team led by Sauer IM,115,156,157 has an integrative
system including the bioreactor unit, the CellModule charged
with primary hepatocytes from porcine or human, and the
detoxication unit, the DetoxModule based on albumin dialy-
sis. In the bioreactor, there is a 3D interwoven ﬁber matrix
by two groups of hydrophilic material and one group of hy-
drophobic material. The hepatocytes are immobilized on it.
The plasma passes through one group of the hydrophilic ﬁber
and contacts with the cells cultured in the extracavity space,
then ﬂows out by another group of hydophilic ﬁber. The
hydrophobic ﬁber supplies oxygen and removes CO2. The
bioreactor has high performance of mass exchange so that it
can load 500–600 g of liver cells. In addition, MELS is the
only one that uses the primary human cells harvested from
the discarded liver tissue or organ in its system.158
In one of its phase I clinical studies,159 MELS loaded with
primary porcine hepatocytes was used for the treatment of
eight patients with ALF of different etiology for 8–46 h, all
patients tolerated the treatment well and were successfully
bridged to the liver transplant with 100% of 3 year survival.
No adverse events associated with the treatment were ob-
served. No PERV infection was discovered in the patients.
In another clinical trial of MELS using human primary
hepatocytes, the bioreactor was charged with human cells
harvested from discarded grafts, and was integrated to the
albumin-dialysis detoxication unit. After 7–144 h treatment,
the neurological symptoms and blood coagulation function
of all the eight patients were improved without adverse
complications.158
F. Radial-ﬂow bioreactor bioartiﬁcial liver
Radial-ﬂow bioreactor RFB bioartiﬁcial liver, developed
by the University of Ferrara, Morsiani et al.,160 has the biore-
actor in which the afferent ﬂuid perfuses from the center to
the periphery while passing through the cells growing in the
apartment. 200–230 g freshly isolated porcine hepatocytes
are charged in the bioreactor and seeded on the polyester
mesh, which is sandwiched between two layers of polyester
sheets to prevent cell leakage.
In the pilot phase I clinical trial of RFB bioartiﬁcial
liver,127 seven ALF patients with hepatic coma grade II to IV
received 6–24 h of treatment. Six of them were successfully
bridged to liver transplant: The neurological symptoms and
coagulation function were improved; the concentration levels
of blood ammonia and bilirubin level decreased by 33% and
11%. No complications such as hemodynamic instability,
PERV infection, and immune rejection were observed. All
the above results illustrate the clinical potential of the RFB
bioartiﬁcial liver.
With the development of more than 20 years, EBAL has
shown its effect in the preclinical trials of signiﬁcant im-
provement of the survival of ALF animal models.161–164
However, how to rationally design and perform the evalua-
tion of the effectiveness of EBAL treatment remains a crucial
issue in the clinical trials. Currently the survival of patients is
the most commonly adopted indicator for the efﬁcacy evalu-
ation of EBAL, but once possible, according to the standard
therapy, the ALF patients meeting the inclusion criteria of the
clinical trials will move to undergo liver transplant only after
a short term of EBAL treatment, and the survival is domi-
nantly determined by the surgery effect; thus it is difﬁcult to
identify whether the survival improvement is due to EBAL
or liver transplantation. The other important indicators for
efﬁcacy evaluation of EBAL, such as blood concentration of
ammonia and bilirubin, or neurological symptoms, most of
them can be inﬂuenced by both the biological and the artiﬁ-
FA128 Wang et al.: Current development of bioreactors for extractor FA128
Biointerphases, Vol. 5, No. 3, September 2010
cial parts of the EBAL system; therefore how to discriminate
the difference of their roles in the EBAL performance is
worthy of more consideration.
There are lots of diversities in the etiology and severity of
the ALF or ACLF. Considering to such complexity, how to
properly individualize the EBAL treatment for different pa-
tients, mainly including indications, contraindications, treat-
ment time course, frequency, interval, etc., can also have a
serious impact on the ﬁnal therapy results.
VI. CONCLUSION
In general, due to the complexity of both the treated sub-
ject and the system itself, it remains enormously challenging
to extensively carry out the large, randomized controlled,
multicenter clinical trials for such an advanced therapy until
now. For the purpose of clinical application, the current re-
quirements for the EBAL bioreactor design can be summa-
rized as follows: 1 To achieve highly efﬁcient two-way
mass exchange between the plasma and the liver cells to
meet the needs for maintenance of liver cell metabolism,
detoxiﬁcation, and synthetic functions.148 2 To simulate the
in vivo microenvironment of liver tissue and provide consis-
tent and sufﬁcient support for long-term maintenance of liver
cell function and viability, by a the improvement of the
oxygen supply by independent channels for oxygen supply,
amendment of extra oxygenators to the system;148 or expan-
sion the distribution of oxygen;152 the addition of the oxygen
carriers such as calf red blood cells,165
perﬂuorocarbons;166,167 b Optimization of the bioreactor
microenvironment, by mimicking the oxygen and nutrient
concentration gradient of liver tissue in vivo, which may be
helpful for the liver cells to re-establish their performance
before isolation;168 c improvement of the technology of
hepatocyte isolation and cultivation, such as coculture with
nonparachymal cells to enhance hepatocyte function; inves-
tigation of the advanced material and construct of the sup-
portive scaffold; 3 to facilitate dynamic monitoring the
changes of function and biochemical parameters within the
bioreactor;148 and 4 to be easy for cryopreservation, trans-
port, and assembly to fully suit the clinical practice.
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